Business
BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer
CryoStor® Freezer Media, evo® Smart Shipper and SciSafe® Storage Services All Utilized to Support Potential Q4 US Regulatory Approval and 2022 Commercial
About this update from Biolife Solutions, Inc.
[{"type":"text","content":"CryoStor® Freezer Media, evo® Smart Shipper and SciSafe® Storage Services All Utilized to Support Potential Q4 US Regulatory Approval and 2022 Commercial Launch\n\n\nBOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze media, evo cold chain management platform and SciSafe storage services with Stirling UltraCold freezers are all being utilized by this top 10 largest global pharmaceutical company to support the anticipated regulatory approval and commercial launch of a new CAR T-cell therapy.\n\n \n \n \n \n \n \n\n \nMike Rice, BioLife's Chairman and CEO, commented, \"This is another relevant example of how we are leveraging our relationships with cell and gene therapy companies to expand our engagements by providing multiple bioproduction tools and services used in manufacturing, storage and distribution. Our class-defining CryoStor biopreservation media and evo cold chain management platform, and state-of-the-art and secure biostorage services and facilities enable research teams to focus on what matters most to them – to improve the lives of patients through the discovery, manufacturing and commercialization of biologic medicines that can prevent, treat, and cure some of the world's most life-threatening diseases.\" \nTo date, BioLife's CryoStor freeze media is exclusively used in the manufacturing process of every dose of the following approved biologic therapies. \nYESCARTA® from Kite, a GILEAD company, approved in the USA, EU, Japan, and China ZYNTEGLO™ from bluebird bio, approved in the EU BREYANZI® from Bristol Myers Squibb, approved in the USA and Japan TECARTUS® from Kite/Gilead, approved in the USA SKYSONA™ from bluebird bio, approved in the EU ABECMA® from Bristol Myers Squib and bluebird bio, approved in the USA, EU, and Canada Undisclosed – approved outside the USACryoStor is also exclusively embedded in the manufacturing and the final drug formulation of 3 additional cell therapies that could receive regulatory approval in the next 3-4 quarters.\nAbout BioLife Solutions\nBioLife Solutions is a leading supplier of cell and gene ther...